Human bile contains MicroRNA‐laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis

Cholangiocarcinoma (CCA) presents significant diagnostic challenges, resulting in late patient diagnosis and poor survival rates. Primary sclerosing cholangitis (PSC) patients pose a particularly difficult clinical dilemma because they harbor chronic biliary strictures that are difficult to distinguish from CCA. MicroRNAs (miRs) have recently emerged as a valuable class of diagnostic markers; however, thus far, neither extracellular vesicles (EVs) nor miRs within EVs have been investigated in human bile. We aimed to comprehensively characterize human biliary EVs, including their miR content. We have established the presence of extracellular vesicles in human bile. In addition, we have demonstrated that human biliary EVs contain abundant miR species, which are stable and therefore amenable to the development of disease marker panels. Furthermore, we have characterized the protein content, size, numbers, and size distribution of human biliary EVs. Utilizing multivariate organization of combinatorial alterations (MOCA), we defined a novel biliary vesicle miR‐based panel for CCA diagnosis that demonstrated a sensitivity of 67% and specificity of 96%. Importantly, our control group contained 13 PSC patients, 16 with biliary obstruction of varying etiologies (including benign biliary stricture, papillary stenosis, choledocholithiasis, extrinsic compression from pancreatic cysts, and cholangitis), and 3 with bile leak syndromes. Clinically, these types of patients present with a biliary obstructive clinical picture that could be confused with CCA. Conclusion: These findings establish the importance of using extracellular vesicles, rather than whole bile, for developing miR‐based disease markers in bile. Finally, we report on the development of a novel bile‐based CCA diagnostic panel that is stable, reproducible, and has potential clinical utility. (Hepatology 2014;60:896–907)

[1]  R. Witek,et al.  Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. , 2009, Gastroenterology.

[2]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[3]  G. Illei,et al.  The Majority of MicroRNAs Detectable in Serum and Saliva Is Concentrated in Exosomes , 2012, PloS one.

[4]  C. Swanton,et al.  Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. , 2012, Journal of hepatology.

[5]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[6]  E. Burdick,et al.  Technology Assessment in the Coronary Artery Surgery Study , 1991, International Journal of Technology Assessment in Health Care.

[7]  C. Scarlett,et al.  Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI‐TOF MS in malignant bile duct stricture , 2006, Hepatology.

[8]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Scott E Kern,et al.  Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. , 2012, Cancer research.

[10]  J. Haier,et al.  MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. , 2010, European journal of cancer.

[11]  Y. Mizuguchi,et al.  Real-Time PCR-Based Analysis of the Human Bile MicroRNAome Identifies miR-9 as a Potential Diagnostic Biomarker for Biliary Tract Cancer , 2011, PloS one.

[12]  N. Reiner,et al.  Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes , 2011, Cellular microbiology.

[13]  S. Mathivanan,et al.  Exosomes: extracellular organelles important in intercellular communication. , 2010, Journal of proteomics.

[14]  R. Karchin,et al.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response. , 2013, Cancer research.

[15]  G. Gores,et al.  Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[16]  J. Lötvall,et al.  Isolation and Characterization of RNA-Containing Exosomes , 2012, Journal of visualized experiments : JoVE.

[17]  T. Patel,et al.  Cholangiocarcinoma—controversies and challenges , 2011, Nature Reviews Gastroenterology &Hepatology.

[18]  J. Bruix,et al.  Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma , 2009, Hepatology.

[19]  Wen-Lang Lin,et al.  Intercellular nanovesicle‐mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth , 2011, Hepatology.

[20]  N. LaRusso,et al.  Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[21]  David L. Masica,et al.  Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. , 2011, Cancer research.

[22]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[23]  G. Gores,et al.  The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis , 2005, Digestive Diseases and Sciences.

[24]  G. Gores,et al.  Classification, diagnosis, and management of cholangiocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  G. Gores,et al.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.